Please try another search
For the nine months ended 31 December 2018, Spring Pharmaceutical Group Inc revenues increased 23% to $59.1M. Net income increased 46% to $12.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Interest income increase of 24% to $110K (income). Basic Earnings per Share excluding Extraordinary Items increased from $0.30 to $0.43.
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Revenue | 19.49 | 18.68 | 20.89 | 16.73 |
Gross Profit | 8.82 | 8.07 | 8.92 | 6.65 |
Operating Income | 5.93 | 5.57 | 6.13 | 3.34 |
Net Income | 4.34 | 4.08 | 4.49 | 2.56 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Assets | 114.3 | 109.56 | 108.74 | 110.14 |
Total Liabilities | 5.35 | 5.22 | 4.48 | 5.03 |
Total Equity | 108.95 | 104.34 | 104.26 | 105.11 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 13.79 | 9.94 | 4.16 | 17.87 |
Cash From Investing Activities | -0.74 | -0.78 | -0.26 | -4.54 |
Cash From Financing Activities | ||||
Net Change in Cash | 10.61 | 6.6 | 2.51 | 15.04 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review